@article{oai:shiga-med.repo.nii.ac.jp:00003636,
 author = {野田, 哲史 and 平, 大樹 and 大崎, 理英 and 藤本, 剛英 and 飯田, 洋也 and 田中, 佐智子 and 安藤, 朗 and 谷, 眞至 and 池田, 義人 and 森田, 真也 and 寺田, 智祐 and NODA, Satoshi and HIRA, Daiki and OSAKI, Rie and FUJIMOTO, Takehide and IIDA, Hiroya and Tanaka-Mizuno, Sachiko and ANDOH, Akira and TANI, Masaji and IKEDA, Yoshito and MORITA, Shin-ya and TERADA, Tomohiro},
 issue = {1},
 journal = {Cancer chemotherapy and pharmacology},
 month = {Jul},
 note = {Purpose:
Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC)., Methods:
This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS)., Results:
The median sorafenib concentration was 2.91 μg/mL (range 0.74-8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54-0.93; p <0.05] and 1.40 μg/mL (AUC 0.97, 95% CI 0.97-1.00; p <0.05), respectively. OS of patients with sorafenib 1.40-3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40-3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)]., Conclusions:
From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40-3.45 μg/mL in patients with HCC., Journal Article},
 pages = {129--139},
 title = {Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.},
 volume = {86},
 year = {2020}
}